BACKGROUND: Long-term survivors of testicular cancer (TC) who received cisplatin-based chemotherapy have an increased risk of cardiovascular disease. A cross-sectional study was performed to objectively assess cardiovascular risk, subclinical atherosclerosis, and endothelial function in long-term survivors of TC. METHODS: Long-term survivors of TC underwent evaluation including determination of body mass index (BMI), Framingham relative risk (RR), brachial artery flow-mediated dilatation (FMD), carotid artery intima-media thickness (IMT), soluble intercellular adhesion molecule-1 (sICAM-1), high sensitivity C-reactive protein (hs-CRP), and flow cytometric analysis of peripheral blood for levels of endothelial progenitor cells (EPCs) and circulating endothelial cells (CECs). TC survivors who received chemotherapy were compared with a chemotherapy naive cohort. RESULTS: Twenty-four patients received cisplatin-based chemotherapy (CBCT) and 15 were chemotherapy-naive (CN). The CBCT cohort demonstrated more impairment of brachial artery FMD than the CN group (5.6% vs 8.8%; P = .05). The mean sICAM was also found to be higher in the CBCT cohort compared with the CN group (P = .04). No significant differences between the groups were noted with regard to BMI, Framingham RR, carotid IMT, or hs-CRP. In a subset of patients, TC survivors who received chemotherapy had a significantly increased level of CECs compared with CN patients (P = .04). No significant difference in EPC levels was detected. CONCLUSIONS: Long-term survivors of TC who received chemotherapy demonstrate objective evidence of endothelial injury and dysfunction, a potential mechanism for increased cardiovascular risk.
BACKGROUND: Long-term survivors of testicular cancer (TC) who received cisplatin-based chemotherapy have an increased risk of cardiovascular disease. A cross-sectional study was performed to objectively assess cardiovascular risk, subclinical atherosclerosis, and endothelial function in long-term survivors of TC. METHODS: Long-term survivors of TC underwent evaluation including determination of body mass index (BMI), Framingham relative risk (RR), brachial artery flow-mediated dilatation (FMD), carotid artery intima-media thickness (IMT), soluble intercellular adhesion molecule-1 (sICAM-1), high sensitivity C-reactive protein (hs-CRP), and flow cytometric analysis of peripheral blood for levels of endothelial progenitor cells (EPCs) and circulating endothelial cells (CECs). TC survivors who received chemotherapy were compared with a chemotherapy naive cohort. RESULTS: Twenty-four patients received cisplatin-based chemotherapy (CBCT) and 15 were chemotherapy-naive (CN). The CBCT cohort demonstrated more impairment of brachial artery FMD than the CN group (5.6% vs 8.8%; P = .05). The mean sICAM was also found to be higher in the CBCT cohort compared with the CN group (P = .04). No significant differences between the groups were noted with regard to BMI, Framingham RR, carotid IMT, or hs-CRP. In a subset of patients, TC survivors who received chemotherapy had a significantly increased level of CECs compared with CN patients (P = .04). No significant difference in EPC levels was detected. CONCLUSIONS: Long-term survivors of TC who received chemotherapy demonstrate objective evidence of endothelial injury and dysfunction, a potential mechanism for increased cardiovascular risk.
Authors: A Muscella; C Vetrugno; F Biagioni; N Calabriso; M T Calierno; F Fornai; S A De Pascali; S Marsigliante; F P Fanizzi Journal: Br J Pharmacol Date: 2016-07-22 Impact factor: 8.739
Authors: Mette Sprauten; Thomas H Darrah; Derick R Peterson; M Ellen Campbell; Robyn E Hannigan; Milada Cvancarova; Clair Beard; Hege S Haugnes; Sophie D Fosså; Jan Oldenburg; Lois B Travis Journal: J Clin Oncol Date: 2011-12-19 Impact factor: 44.544
Authors: Mohammad Abu Zaid; Wambui G Gathirua-Mwangi; Chunkit Fung; Patrick O Monahan; Omar El-Charif; Annalynn M Williams; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Ryan Cook; Sandra K Althouse; Shirin Ardeshir-Rouhani-Fard; Paul C Dinh; Howard D Sesso; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis Journal: J Natl Compr Canc Netw Date: 2018-03 Impact factor: 11.908
Authors: Daniel A Mulrooney; Kirsten K Ness; Anna Solovey; Robert P Hebbel; James D Neaton; Bruce A Peterson; Chung K K Lee; Aaron S Kelly; Joseph P Neglia Journal: Pediatr Blood Cancer Date: 2012-03-27 Impact factor: 3.167
Authors: Cindy K Blair; Aaron S Kelly; Julia Steinberger; Lynn E Eberly; Char Napurski; Kim Robien; Joseph P Neglia; Daniel A Mulrooney; Julie A Ross Journal: Pediatr Blood Cancer Date: 2014-08-30 Impact factor: 3.167